Monitoring Solid Organ Transplant Health with Donor-Derived Cell-Free DNA 2

Explore the clinical implementation and benefits of cell-free DNA (cfDNA) as an advanced biomarker for monitoring solid organ transplant patients in this 30-minute webinar. Learn how cfDNA has revolutionized allograft health assessment and rejection detection since the Paris Transplant Group-PITOR established their dedicated platform in 2022. Discover the practical aspects of integrating cfDNA monitoring into routine clinical practice across multiple transplant centers, examining real-world data that demonstrates improved patient follow-up and earlier rejection detection capabilities. Understand how this innovative approach has facilitated the development of new clinical protocols and supported large-scale monitoring with steady growth in sample volume and clinical adoption. Gain insights into the platform's trajectory, key implementation milestones, and the dual integration of cfDNA technology into both clinical care and research settings for enhanced transplant patient management.